-$0.41 EPS Expected for Senesco Technologies Inc. (ELOX) This Quarter

Wall Street brokerages expect Senesco Technologies Inc. (NYSE:ELOX) to report earnings per share of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Senesco Technologies’ earnings, with estimates ranging from ($0.46) to ($0.36). Senesco Technologies reported earnings per share of ($0.31) in the same quarter last year, which would indicate a negative year over year growth rate of 32.3%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Senesco Technologies will report full-year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.93) to ($1.52). For the next financial year, analysts anticipate that the company will report earnings of ($1.73) per share, with EPS estimates ranging from ($1.90) to ($1.63). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Senesco Technologies.

Senesco Technologies (NYSE:ELOX) last released its quarterly earnings results on Friday, March 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.03).

Separately, HC Wainwright restated a “neutral” rating on shares of Senesco Technologies in a research report on Monday, December 24th.

Shares of ELOX stock traded up $0.63 during trading hours on Friday, hitting $11.23. The company’s stock had a trading volume of 33,156 shares, compared to its average volume of 30,745. Senesco Technologies has a twelve month low of $9.12 and a twelve month high of $24.60.

Senesco Technologies Company Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Read More: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Senesco Technologies (ELOX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senesco Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies and related companies with MarketBeat.com's FREE daily email newsletter.